Clinical Efficacy, Drug Safety, and Surrogate Endpoints: Has Aducanumab Met All of Its Expectations?

Neurology. 2021 Sep 14;97(11):517-518. doi: 10.1212/WNL.0000000000012453. Epub 2021 Jul 7.

Authors

Linda A Hershey¹, Rawan Tarawneh²

Affiliations

¹ From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Department of Neurology (R.T.), The Ohio State University, Columbus. linda-hershey@ouhsc.edu.
² From the Department of Neurology (L.A.H.), University of Oklahoma Health Sciences Center, Oklahoma City; and Department of Neurology (R.T.), The Ohio State University, Columbus.

PMID: 34233940
DOI: 10.1212/WNL.0000000000012453

No abstract available

Publication types

Editorial

MeSH terms

Alzheimer Disease / drug therapy*
Antibodies, Monoclonal, Humanized / therapeutic use*
Clinical Trials as Topic
Endpoint Determination
Humans
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
aducanumab

Grants and funding

R21 AG067755/AG/NIA NIH HHS/United States